TP53 and chronic kidney disease: Targeting cell cycle arrest is a potential innovative strategy to improve kidney repair and prevent CKD, as studies targeting p21, p53, Cyclin G1 (CG1) and HDAC inhibitors have progressed in animal experiments (Skrypnyk et al., 2016; Fu et al., 2017; Canaud et al., 2019).